Incyte stock rises following EHA presentation acceptance

Published 03/06/2025, 16:02
© Reuters.

Investing.com -- Shares of Incyte (NASDAQ:INCY) climbed 7% today after the biopharmaceutical company announced that multiple presentations, including new late-breaking data for its monoclonal antibody INCA033989, have been accepted for presentation at the upcoming European Hematology Association (EHA) congress.

The company’s press release detailed that the late-breaking oral presentation will showcase findings from a trial of INCA033989, which targets mutant calreticulin (mutCALR) in patients with essential thrombocythemia (ET). The data is set to be presented at the EHA congress scheduled from June 12 to 15, 2025, in Milan.

Incyte’s president and head of research and development, Dr. Pablo J. Cagnoni, expressed optimism about the potential of INCA033989 as a disease-modifying agent for myeloproliferative neoplasms (MPNs) like ET. The company plans to host an in-person analyst and investor event to discuss the mutCALR data on Sunday, June 15, 2025.

In addition to INCA033989, Incyte will present data on various other programs within its hematology/oncology portfolio, including oral presentations on INCA035784, a T cell redirecting antibody, and clinical outcomes related to the use of Ruxolitinib for myelofibrosis with anemia. Poster presentations will cover a range of topics, such as the Phase 3 study of Axatilimab for chronic graft-versus-host disease and the efficacy of the BET protein inhibitor INCB057643 in myeloid neoplasms.

Investors have responded positively to the news, reflected in the stock’s upward movement.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.